CRISPR Therapeutics AG (CRSP) came out with quarterly earnings of $9.44 per share, beating the Zacks Consensus Estimate of $4.19 per share. This compares to loss of $1.30 per share a year ago. These ...

CRISPR Therapeutics AG (NASDAQ:CRSP) ranks among the best short squeeze stocks to buy right now. Citizens reaffirmed its ...

This includes the labeling of the dCas9 protein, engineering of sgRNA, and the use of dCas9 orthologs from different bacterial species. CRISPR, clustered regularly interspaced short palindromic ...

CRISPR Therapeutics AG (CRSP) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...

CRISPR Therapeutics and BioNTech have climbed along with many of their peers over the past week. Both are innovative biotechs with catalysts that could drive their stocks higher in the next few years.

On Hump Day, investors piled into CRISPR Therapeutics (NASDAQ: CRSP) stock, sending its price more than 9% higher at the trading session's close. They were highly encouraged by the specialized ...

A new way to eradicate HIV from the body could one day be turned into a cure for infection by this virus, although it hasn’t yet been shown to work in people. The strategy uses a relatively recent ...